Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ARB202 (atezolizumab) is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: ARB202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
ARB202 is a first-in-class bispecific antibody based on Abele's patented CDH17 biomarker. The unique differential binding affinities of ARB202 toward CDH17 and CD3 allows it to have high specificity and cytotoxicity, while avoiding the "off-target" overactivation of T cells.
Lead Product(s): ARB202,Atezolizumab
Therapeutic Area: Oncology Product Name: ARB202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022